ArticleOncogene1999
HuD, a neuronal-specific RNA-binding protein, is a putative regulator of N-myc pre-mRNA processing/stability in malignant human neuroblasts.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation.bioRxiv : the preprint server for biology · 2026Article
- Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis.Frontiers in immunology · 2025Review
- The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.Nature communications · 2023Article
- Article
- RNA binding protein HuD promotes autophagy and tumor stress survival by suppressing mTORC1 activity and augmenting ARL6IP1 levels.Journal of experimental & clinical cancer research : CR · 2022Article
- MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma.Frontiers in oncology · 2022Article
- Regulation of the Alternative Neural Transcriptome by ELAV/Hu RNA Binding Proteins.Frontiers in genetics · 2022Review
- Roles of Embryonic Lethal Abnormal Vision-Like RNA Binding Proteins in Cancer and Beyond.Frontiers in cell and developmental biology · 2022Review
- The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.Frontiers in oncology · 2021Article
- Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma.International journal of molecular sciences · 2020Article
- Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.Oncology reports · 2017Article
- A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.Stem cell research · 2015Article
- A cell-based high-throughput screen addressing 3'UTR-dependent regulation of the MYCN gene.Molecular biotechnology · 2014Article
- Post-transcriptional regulatory elements and spatiotemporal specification of neocortical stem cells and projection neurons.Neuroscience · 2013Review
- Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction.RNA (New York, N.Y.) · 2013Review
- Article
- Cooperative action of multiple cis-acting elements is required for N-myc expression in branchial arches: specific contribution of GATA3.Molecular and cellular biology · 2010Article
- CompMoby: comparative MobyDick for detection of cis-regulatory motifs.BMC bioinformatics · 2008Article
- Closing the phenotypic gap between transformed neuronal cell lines in culture and untransformed neurons.Journal of neuroscience methods · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-myc gene copy numbers and transcription rates are similar in N (neuroblastic, tumorigenic) and S (non-neuronal, non-tumorigenic) neuroblastoma cells with chromosomally integrated amplified N-myc genes. However, N cells show significantly higher N-myc mRNA levels than S cells. Therefore, post-transcriptional control of N-myc gene expression must differ between these cell types. Since no differences in N-myc mRNA half-life were found between N and S cells from two cell lines, steady-state levels of N-myc pre-mRNA processing intermediates were analysed. Results suggest that the differences in N-myc expression arise primarily at the nuclear post-transcriptional level. The neuronal-specific RNA-binding Hu proteins are present in cytoplasmic and nuclear fractions of N cells and one of them, HuD, binds specifically to both exonic and intronic N-myc RNA sequences. In sense and antisense HuD-transfected N cells, there are coordinate changes in HuD and N-myc expression levels. Thus, we propose that HuD plays a role in the nuclear processing/stability of N-myc pre-mRNA in N-type neuroblastoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.